Skip to main content

Table 1 Patient demographics and baseline characteristics of the AMBITION cohort, according to treatment group. Differences between treatment groups are presented by one-way ANOVA t test

From: Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study

Characteristics Tocilizumab, N = 164 Methotrexate, N = 161 Placebo, N = 62 P value
Age (years), mean (SD) 50.7 (12.9) 51.3 (13.3) 50.5 (11.8) ns
Female, n (%) 131 (80) 122 (76) 47 (76) ns
Male, n (%) 33 (20) 39 (24) 15 (24) ns
DAS28, mean (SD) 6.8 (0.9) 6.8 (0.9) 6.9 (0.9) ns
BMI (SD) 28.1 (6.4) 27.4 (6.0) 29.1 (7.4) ns
TJC, mean (SD) 32.6 (14.8) 32.1 (14.1) 35.4 (16.3) ns
SJC, mean (SD) 19.4 (10.9) 19.9 (10.6) 23.5 (12.2) P = 0.04
RADUR (SD) 6.7 (8.1) 6.6 (8.0) 7.4 (9.0) ns
CRP (mg/dL), mean (SD) 3.2 (3.6) 3.1 (3.5) 2.5 (2.7) ns
ESR (mm/h), mean (SD) 46.9 (26.1) 47.9 (24.1) 48.2 (22.4) ns
HAQ-DI, mean (SD) 1.6 (0.6) 1.6 (0.6) 1.4 (0.5) ns
Pain VAS 100 mm, mean (SD) 59.0 (22.4) 61.3 (20.7) 59.5 (24.4) ns
Patient VAS 100 mm, mean (SD) 64.6 (22.0) 64.9 (19.4) 64.3 (22.5) ns
Physician VAS 100 mm, mean (SD) 63.5 (16.1) 64.6 (16.3) 69.1 (17.9) ns
Baseline C1M (ng/mL), mean (95% CI) 42.7 (37.5–47.8) 45.2 (39.4–50.9) 40.5 (34.5–46.5) ns
Baseline C2M (ng/mL), mean (95% CI) 0.4 (0.4–0.5) 0.4 (0.4–0.5) 0.3 (0.3–0.4) ns
Baseline C3M (ng/mL), mean (95% CI) 17.8 (16.5–19.2) 18.3 (17.1–19.5) 15.9 (13.8–17.9) ns
Baseline C4M (ng/mL), mean (95% CI) 53.9 (49.3–58.4) 51 (47.2–54.8) 42.3 (36.5–48.1) P = 0.02
Baseline CRPM (ng/mL), mean (95% CI) 21.9 (19.6–24.2) 20.8 (18.9–22.8) 18.5 (15.0–21.9) ns
Baseline CRP (ng/mL), mean (95% CI) 3.2 (2.6–3.8) 3.1 (2.6–3.7) 2.5 (1.8–3.2) ns
  1. DAS28 28-Joint Disease Activity Score, TJC tender joint count, SJC swollen joint count, CRP C-reactive protein, ESR erythrocyte sedimentation rate, HAQ-DI Health Assessment Questionnaire-Disability Index, VAS visual analogue scale